Sixth Consecutive "Best CRO" Award Nomination for Accelovance
ROCKVILLE, Md., March 26, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc., a Maryland based contract research organization (CRO), was nominated for the 2013 ViE "Best CRO" Award for the sixth year in a row and is a confirmed finalist in this award category. Therapeutically focused on vaccines, infectious disease, immunology and oncology, Accelovance was a recipient of the award, as determined by an international panel of independent judges, previously in 2009, 2010 and 2011. The award complements a strong first quarter that announced strong leadership team additions and a successful CRO acquisition earlier this month.
"This nomination is a reflection of how we have served clients over the past 12-18 months with a diverse offering; flexible CRO services, research dedicated Vaccine Centers of Excellence and our Patient Recruitment solutions that include our Clinical Call Center," commented Stephen J. Trevisan, President and Chief Executive Officer. "It is an honor to be recognized again and again as one of the best in the industry, in this niche space."
The World Vaccine Congress – Washington and its annual Vaccine Industry Excellence (ViE) Awards reception will be held in late April at the Gaylord National Harbor facility in Maryland. The ViE awards were established to honor the excellence and accomplishments of vaccine and infectious disease service providers, Sponsors, Non Government Organizations (NGOs), clinical sites, manufacturers and strategic partnerships.
Since its inception in 2005, Accelovance has catered to the niche market of vaccines and infectious disease with cost-effective, integrated clinical solutions that accelerate study timelines and also reduce overall study costs. Fixed price budgets and performance guarantees have helped define the level of execution and control Accelovance brings to such studies. Over the past 12 months, Accelovance has supported government-funded Sponsors, top five vaccine manufacturers and biotech companies in Phase I-IV clinical studies; several First in Man and Phase III pivotal programs. These have included novel manufacturing methods, unique delivery methods, biodefense programs and traditional vaccines for pediatric, adolescent, adult and elderly populations.
Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The Company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. Accelovance tailors its offering of full CRO, Clinical Sites, Patient Recruitment and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world. Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability and quality assurance to therapeutically aligned studies.
For more information, visit the company's website at http://www.accelovance.com.
Garrett D. Smith